ZBH · NYSE
Zimmer Biomet Holdings, Inc.
$95.31 -2.04 (-2.10%)
Company overview
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants and dental prosthetic and regenerative products, as well as robotic, surgical, and bone cement products.
- Sector
- Healthcare
- Industry
- Medical - Devices
- Exchange
- NYSE
- Market cap
- $18.2B
- Employees
- 17,000
- Headquarters
- Warsaw, IN
- Website
- zimmerbiomet.com
- CEO
- Ivan Tornos
- Listed
- July 25, 2001
- P/E
- 24.66
- Dividend yield
- 1.08%
Company financials
- Revenue
- $8.4B
- Gross profit
- $5.9B
- Operating income
- $1.3B
- EBITDA
- $2.2B
- Net income
- $761M
- EPS
- $3.87
- Total assets
- $22.7B
- Total debt
- $7.5B
- Gross margin
- 70.03%
- Net margin
- 9.05%
- Earnings yield
- 4.06%
Showing FY 2025
ZBH
1D
NYSE
O97.60H97.92L96.26C97.35+0.96 (+1.00%)Vol608.04K